Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference

Rhea-AI Summary

Fulgent Genetics (NASDAQ: FLGT) has announced that its CFO, Paul Kim, and CCO, Brandon Perthuis, will present virtually at the H.C. Wainwright BIOCONNECT 2021 Conference from January 11-14, 2021. A webcast of the presentation will be available at 6:00 a.m. ET on January 11 on the company’s Investor Relations page and accessible for 90 days. Fulgent Genetics specializes in comprehensive testing solutions and has launched various tests for SARS-CoV-2, receiving Emergency Use Authorization from the FDA for its RT-PCR tests.

TEMPLE CITY, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent Genetics” or the “company”), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that its Chief Financial Officer Paul Kim, and Chief Commercial Officer Brandon Perthuis are scheduled to virtually participate in a presentation at the H.C. Wainwright BIOCONNECT 2021 Conference taking place January 11 to 14, 2021.

A webcast of the presentation will be available beginning at 6:00 a.m. ET on January 11, 2021 on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com, and will be available for 90 days following the conference.

About Fulgent Genetics

Fulgent Genetics’ proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (“NGS”) with its technology platform, the Company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the Company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the Company’s advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the Company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (“COVID-19”), including NGS and reverse transcription polymerase chain reaction (“RT-PCR”) - based tests. The Company has received Emergency Use Authorization (“EUA”) from the U.S. Food and Drug Administration (“FDA”) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the Company’s business is its ability to provide expansive options and flexibility for all clients’ unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633; nicole@blueshirtgroup.com

 

FAQ

When is Fulgent Genetics presenting at the H.C. Wainwright BIOCONNECT 2021 Conference?

Fulgent Genetics is scheduled to present from January 11 to 14, 2021.

Who from Fulgent Genetics will participate in the conference?

CFO Paul Kim and CCO Brandon Perthuis will participate in the conference.

Where can I watch the Fulgent Genetics conference presentation?

The presentation will be available on the company's Investor Relations website starting January 11, 2021.

What services does Fulgent Genetics provide?

Fulgent Genetics offers comprehensive testing solutions, including next generation sequencing and tests for SARS-CoV-2.

Has Fulgent Genetics received any FDA authorizations?

Yes, Fulgent Genetics has received Emergency Use Authorization from the FDA for its RT-PCR tests for SARS-CoV-2.